Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update

Completes SYMON-II clinical study enrollment and advances clinical validation activities.Achieves critical manufacturing milestone ahead of contractual deadline, strengthening supply chain and commercialization readiness.Targets FDA 510(k) submission in the first half of 2027.ACTON, MA / ACCESS New…